{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:22:36Z","timestamp":1787840556853,"version":"build-2784847793"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Diverse biological therapies have become increasingly prevalent in recent years in the treatment of psoriasis. However, current guidelines continue to recommend non-biological systemic treatments. Real-life data on the survival of acitretin and methotrexate are limited. It is important to determine the appropriate patient candidates before treatment and to determine the factors affecting survival to increase treatment compliance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims and Objectives:<\/jats:title>\n                    <jats:p>This study aimed to calculate the estimated survival and 1-, 2-, 3-, 5-year survival rates of acitretin and methotrexate and to determine the factors affecting survival. Other purposes include evaluating reasons for treatment cessation, and adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Our retrospective study, conducted at a single centre, included 364 adult patients diagnosed with psoriasis who had received at least one of the acitretin or methotrexate and had at least two visit records. The data were obtained from patient records. Response to treatment in the third month, adverse effects, and reasons for treatment discontinuation were recorded. Survival analysis was performed using the Kaplan\u2013Meier method. Log-rank tests and Cox regression analyses were used to assess the predictive factors for survival.\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.05 was considered significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 437 treatment courses of 364 patients were evaluated. The median follow-up was 39.5 (21.00\u201364.75) months. The median survival was calculated as 14 months for acitretin and 20 months for methotrexate. One-year drug survival rates for acitretin and methotrexate were 49.5% and 62.7%, respectively. Treatment response was the most important determinant of drug survival for both medications, whereas advancing age and arthritis had a positive effect on methotrexate survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Survival rates of acitretin and methotrexate were generally low in practice compared with published data on biological treatments, but as a response to treatment increased, the survival of both drugs improved. Better strategies need to be developed to increase treatment response and survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_1154_23","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:00:23Z","timestamp":1761127223000},"page":"24-29","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Drug Survival of Acitretin and Methotrexate in Adult Psoriasis Patients"],"prefix":"10.4103","volume":"71","author":[{"given":"Merve Hatun","family":"Erkayman","sequence":"first","affiliation":[{"name":"From the Department of Dermatology and Venereology, Ataturk University, Erzurum, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00fclin","family":"Ergun","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, School of Medicine, Marmara University, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"R1-20251231","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"R2-20251231","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris-Part 1:Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R3-20251231","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American academy of dermatology-national psoriasis foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R4-20251231","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjd.13343","article-title":"Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris","volume":"172","author":"Gniadecki","year":"2015","journal-title":"Br J Dermatol"},{"key":"R5-20251231","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjd.15305","article-title":"Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation:Results of the prospective MTX-CAPTURE","volume":"177","author":"Otero","year":"2017","journal-title":"Br J Dermatol"},{"key":"R6-20251231","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2340\/00015555-2130","article-title":"Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis","volume":"95","author":"Shalom","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"R7-20251231","doi-asserted-by":"crossref","first-page":"e14834","DOI":"10.1111\/dth.14834","article-title":"Drug survival and safety profile of acitretin monotherapy in patients with psoriasis:A multicenter retrospective study","volume":"34","author":"Kara Polat","year":"2021","journal-title":"Dermatol Ther"},{"key":"R8-20251231","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1159\/000452740","article-title":"Efficacy and survival of systemic psoriasis treatments:An analysis of the Swiss registry SDNTT","volume":"232","author":"Maul","year":"2016","journal-title":"Dermatology"},{"key":"R9-20251231","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/09546634.2016.1273469","article-title":"Effectiveness and safety of methotrexate in psoriasis:An eight-year experience with 218 patients","volume":"28","author":"Cabello Zurita","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"R10-20251231","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/ijd.15628","article-title":"Drug survival and predictor factors for discontinuation of methotrexate in psoriasis:A real-life multicenter study","volume":"60","author":"Ozkok Akbulut","year":"2021","journal-title":"Int J Dermatol"},{"key":"R11-20251231","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/bjd\/ljad004","article-title":"Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis:A cohort study from BADBIR","volume":"188","author":"Alabas","year":"2023","journal-title":"Br J Dermatol"},{"key":"R12-20251231","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/1346-8138.13713","article-title":"Efficacy, safety and drug survival of conventional agents in pediatric psoriasis:A multicenter, cohort study","volume":"44","author":"Ergun","year":"2017","journal-title":"J Dermatol"},{"key":"R13-20251231","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/ddg.13152","article-title":"Drug survival rates and reasons for drug discontinuation in psoriasis","volume":"14","author":"Arnold","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"R14-20251231","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/ijd.14349","article-title":"Long-term safety and drug survival of acitretin in psoriasis:A retrospective observational study","volume":"58","author":"Chularojanamontri","year":"2019","journal-title":"Int J Dermatol"},{"key":"R15-20251231","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/jdv.13682","article-title":"Survival of classic and biological systemic drugs in psoriasis:Results of the BIOBADADERM registry and critical analysis","volume":"30","author":"D\u00e1vila-Seijo","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R16-20251231","first-page":"273","article-title":"Adverse effects of retinoids","volume":"3","author":"David","year":"1988","journal-title":"Med Toxicol Adverse Drug Exp"},{"key":"R17-20251231","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archderm.142.8.1000","article-title":"Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis","volume":"142","author":"Pearce","year":"2006","journal-title":"Arch Dermatol"},{"key":"R18-20251231","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1468-3083.2000.00058.x","article-title":"Methotrexate in psoriasis:26 years'experience with low-dose long-term treatment","volume":"14","author":"Haustein","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R19-20251231","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/RHU.0000000000000810","article-title":"Folate Supplementation for methotrexate therapy in patients with rheumatoid arthritis:A systematic review","volume":"25","author":"Liu","year":"2019","journal-title":"J Clin Rheumatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_1154_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:24:59Z","timestamp":1787837099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_1154_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_1154_23","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"2023-12-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}